Characterization of the biochemical activity and tumor-promoting role of the dual protein methyltransferase METL-13/METTL13 in Caenorhabditis elegans

PLoS One. 2023 Jun 22;18(6):e0287558. doi: 10.1371/journal.pone.0287558. eCollection 2023.

Abstract

The methyltransferase-like protein 13 (METTL13) methylates the eukaryotic elongation factor 1 alpha (eEF1A) on two locations: the N-terminal amino group and lysine 55. The absence of this methylation leads to reduced protein synthesis and cell proliferation in human cancer cells. Previous studies showed that METTL13 is dispensable in non-transformed cells, making it potentially interesting for cancer therapy. However, METTL13 has not been examined yet in whole animals. Here, we used the nematode Caenorhabditis elegans as a simple model to assess the functions of METTL13. Using methyltransferase assays and mass spectrometry, we show that the C. elegans METTL13 (METL-13) methylates eEF1A (EEF-1A) in the same way as the human protein. Crucially, the cancer-promoting role of METL-13 is also conserved and depends on the methylation of EEF-1A, like in human cells. At the same time, METL-13 appears dispensable for animal growth, development, and stress responses. This makes C. elegans a convenient whole-animal model for studying METL13-dependent carcinogenesis without the complications of interfering with essential wild-type functions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Caenorhabditis elegans / genetics
  • Carcinogenesis
  • Humans
  • Methyltransferases / genetics
  • Neoplasms*
  • Peptide Elongation Factor 1 / genetics
  • Protein Methyltransferases*

Substances

  • Protein Methyltransferases
  • Methyltransferases
  • Peptide Elongation Factor 1

Grants and funding

This work was supported by the Research Council of Norway grant FRIMEDBIO-286499 to RC, and by the Norwegian Cancer Society's grants 228890 to RC and 207855 to PF. The research leading to these results also received funding from the Norwegian Financial Mechanism 2014–2021 operated by the Polish National Science Center under the project contract nr UMO-2019/34/H/NZ3/00691. Some of the strains were provided by the Caenorhabditis Genetics Center (CGC), funded by the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.